Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Corrigendum: Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance.

Shaffer SM, Dunagin MC, Torborg SR, Torre EA, Emert B, Krepler C, Beqiri M, Sproesser K, Brafford PA, Xiao M, Eggan E, Anastopoulos IN, Vargas-Garcia CA, Singh A, Nathanson KL, Herlyn M, Raj A.

Nature. 2018 Mar 8;555(7695):274. doi: 10.1038/nature25162. Epub 2018 Feb 21.

PMID:
29466340
2.

ATG5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma.

Ndoye A, Budina-Kolomets A, Kugel CH 3rd, Webster MR, Kaur A, Behera R, Rebecca VW, Li L, Brafford PA, Liu Q, Gopal YNV, Davies MA, Mills GB, Xu X, Wu H, Herlyn M, Nicastri MC, Winkler JD, Soengas MS, Amaravadi RK, Murphy ME, Weeraratna AT.

Cancer Res. 2017 Nov 1;77(21):5873-5885. doi: 10.1158/0008-5472.CAN-17-0907. Epub 2017 Sep 8.

3.

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance.

Shaffer SM, Dunagin MC, Torborg SR, Torre EA, Emert B, Krepler C, Beqiri M, Sproesser K, Brafford PA, Xiao M, Eggan E, Anastopoulos IN, Vargas-Garcia CA, Singh A, Nathanson KL, Herlyn M, Raj A.

Nature. 2017 Jun 15;546(7658):431-435. doi: 10.1038/nature22794. Epub 2017 Jun 7. Erratum in: Nature. 2018 Feb 21;:.

4.

Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma.

Fatkhutdinov N, Sproesser K, Krepler C, Liu Q, Brafford PA, Herlyn M, Aird KM, Zhang R.

Mol Cancer Res. 2016 Sep;14(9):767-75. doi: 10.1158/1541-7786.MCR-16-0099. Epub 2016 Jun 13.

5.

Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.

Krepler C, Xiao M, Sproesser K, Brafford PA, Shannan B, Beqiri M, Liu Q, Xu W, Garman B, Nathanson KL, Xu X, Karakousis GC, Mills GB, Lu Y, Ahmed TA, Poulikakos PI, Caponigro G, Boehm M, Peters M, Schuchter LM, Weeraratna AT, Herlyn M.

Clin Cancer Res. 2016 Apr 1;22(7):1592-602. doi: 10.1158/1078-0432.CCR-15-1762. Epub 2015 Dec 16.

6.

PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas.

Lee JT, Li L, Brafford PA, van den Eijnden M, Halloran MB, Sproesser K, Haass NK, Smalley KS, Tsai J, Bollag G, Herlyn M.

Pigment Cell Melanoma Res. 2010 Dec;23(6):820-7. doi: 10.1111/j.1755-148X.2010.00763.x.

7.

A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth.

Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T, Herlyn M.

Cell. 2010 May 14;141(4):583-94. doi: 10.1016/j.cell.2010.04.020.

8.

Active Notch1 confers a transformed phenotype to primary human melanocytes.

Pinnix CC, Lee JT, Liu ZJ, McDaid R, Balint K, Beverly LJ, Brafford PA, Xiao M, Himes B, Zabierowski SE, Yashiro-Ohtani Y, Nathanson KL, Bengston A, Pollock PM, Weeraratna AT, Nickoloff BJ, Pear WS, Capobianco AJ, Herlyn M.

Cancer Res. 2009 Jul 1;69(13):5312-20. doi: 10.1158/0008-5472.CAN-08-3767. Epub 2009 Jun 23.

9.

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases.

Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M.

Mol Cancer Ther. 2006 May;5(5):1136-44.

10.

Defining the conditions for the generation of melanocytes from human embryonic stem cells.

Fang D, Leishear K, Nguyen TK, Finko R, Cai K, Fukunaga M, Li L, Brafford PA, Kulp AN, Xu X, Smalley KS, Herlyn M.

Stem Cells. 2006 Jul;24(7):1668-77. Epub 2006 Mar 30.

11.

Selective evolutionary pressure from the tissue microenvironment drives tumor progression.

Smalley KS, Brafford PA, Herlyn M.

Semin Cancer Biol. 2005 Dec;15(6):451-9. Review.

PMID:
16043361

Supplemental Content

Loading ...
Support Center